Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618294 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2HPGDALDH1A1TLR7TP53 | |
| SCHEMBL5618245 | 0.86 | TLR7 (0.42) | SMN1; SMN2HPGDTLR7GAAMEN1 | |
| SCHEMBL5618033 | 0.86 | TLR7 (0.42) | SMN1; SMN2HPGDTLR7GAAMEN1 | |
| SCHEMBL5617904 | 0.86 | TP53 (0.41) | SMN1; SMN2HPGDALDH1A1TLR7TP53 | |
| SCHEMBL5618007 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDALDH1A1TLR7TP53 | |
| SCHEMBL5618002 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDALDH1A1TLR7TP53 | |
| SCHEMBL5617243 | 0.83 | LMNA (0.43) | SMN1; SMN2HPGDALDH1A1TLR7TP53 | |
| SCHEMBL3176214 | 0.82 | TLR7 (0.49) | SMN1; SMN2HPGDALDH1A1TLR7TP53 | |
| SCHEMBL5617263 | 0.82 | TNF (0.45) | TP53GAAENPP2LMNA | |
| SCHEMBL5618891 | 0.81 | GAA (0.43) | SMN1; SMN2ALDH1A1TLR7TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778963-B2 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099901-A1 | Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | IFNG, IRF3, IDO1 | SMN1; SMN2 3106/4885HPGD 27/4885ALDH1A1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.